Biohaven Shares Surge 7% on $795M SK Biopharmaceuticals Licensing Deal

Biohaven shares rose 7% after announcing a global licensing agreement with SK Biopharmaceuticals for its epilepsy drug candidate.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.